You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncopeptides has announced that the European Commission has granted Pepaxti marketing authorization in combination with dexamethasone. The approval concerns the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractoryAlready a subscriber Login You have read all your free…
Nordic Life Science asked Göran Forsberg, CEO of Cantargia, about Cantargia's future plans and his reactions to the Nobel Prizes. Congratulations on the listing on the main market Nasdaq Stockholm. What does this mean for the company? “Thank you! This means that the company will receive more exAlready a subscriber…
Aqilion has nominated Girtab, a program from the company’s research activities, for further preclinical and clinical development. The goal of Girtab is to develop a new treatment for chronic inflammatory bowel diseases (IBD). Girtab complements Aqilion’s pipeline well and strengthens the compAlready a subscriber Login You have read all your…
The companies have entered into a global exclusive license agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, develoAlready a subscriber Login You have read all your free…
